Transforming Diagnostics
with AI
Join the Revolution in Image-based Diagnostics
Embrace the future of healthcare with Cancilico’s cutting-edge AI technology. Our solutions are designed to enhance accuracy and efficiency in diagnosing diseases such as hematological cancers. Experience the power of innovation in image-based diagnostics.
Our Vision
Cancilico: Pioneering AI in Healthcare
At Cancilico, we are committed to revolutionizing the field of image-based diagnostics. Our vision is to harness the potential of artificial intelligence to streamline and improve the accuracy of critical diagnostic processes. With morphological differentiation of bone marrow smears being one key area of our focus, our innovative technology aims to bring a new era of precision and speed to the diagnosis of hematological cancers. In an industry where every second counts, our solutions promise to deliver faster, more reliable results, aiding clinicians in making timely and informed decisions, thereby enhancing patient care and outcomes.
Our Products and Services
MyeloAID
With our flagship AI software product, MyeloAID, currently in development, we aim to automate the classification and counting of cells in bone marrow samples. Utilizing advanced AI algorithms, MyeloAID is being designed to provide a rapid and accurate analysis of cell types, with ability to create a detailed myelogram in minutes. This innovative solution is anticipated to enhance diagnostic precision, while significantly reducing the time and labor traditionally involved in hematological examinations.
Cancilico's AI Services
Our AI-driven solutions can be tailored to address a wide array of challenges in medical research. From cloud-based platforms for research to specialized algorithms for rare cell type identification, our services are designed to integrate seamlessly with existing laboratory infrastructure, providing a low barrier to entry and delivering high-value outcomes. Our strong commitment to quality and continuous improvement ensures that our solutions consistently meet industry standards and exceed the evolving needs of the medical research community.
Partners
News
Exploring the Future of AI in Medicine: Cancilico’s Experience at the “AI-in-Medicine” Conference
In the rapidly evolving world of medical technology, Cancilico recently had the opportunity to attend the prestigious "AI-in-Medicine" conference, a gathering that showcases the latest advancements and discussions in the field of artificial intelligence in healthcare....
Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
The recent years have brought a lot of advancements in understanding leukemia biology due to comprehensive studies investigating molecular alterations. Risk stratification, however, is still largely restricted to simplistic decision-making models based on singular...
Supervised Learning predicts therapeutic success in acute myeloid leukemia
Achievement of complete remission signifies a crucial milestone in the therapy of acute myeloid leukemia (AML) while refractory disease is associated with dismal outcomes. Hence, accurately identifying patients at risk is essential to tailor treatment concepts...